<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Nitrosourea-induced pulmonary injury
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Nitrosourea-induced pulmonary injury
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Nitrosourea-induced pulmonary injury
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Fabien Maldonado, MD, MSc
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Amanda S Cass, PharmD, BCPS, BCOP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin R Flaherty, MD, MS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James R Jett, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 11, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The nitrosourea drugs, a class of DNA alkylating agents related to nitrogen mustards, include
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         (BiCNU or BCNU, the most widely used nitrosourea),
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         (CCNU), and fotemustine (available in some countries outside the United States). Pulmonary toxicity has been described following treatment with all of these agents [
         <a href="#rid1">
          1-5
         </a>
         ].
        </p>
        <p>
         Nitrosoureas are used predominantly to treat lymphoma, brain tumors, and melanoma, in which treatment usually involves repeated cycles for periods up to two years.
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          Carmustine
         </a>
         and
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         are also used in single dose or short course preparative regimens for hematopoietic cell transplantation (HCT) in combination with other chemotherapy agents [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         The clinical characteristics and management of pulmonary toxicity associated with nitrosoureas will be reviewed here. Pulmonary complications of allogeneic and autologous hematopoietic cell transplantation and pulmonary toxicity due to other antineoplastic agents are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4342.html" rel="external">
          "Pulmonary complications after autologous hematopoietic cell transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">
          "Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4315.html" rel="external">
          "Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4327.html" rel="external">
          "Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4336.html" rel="external">
          "Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1077867">
         <span class="h1">
          IDIOPATHIC PNEUMONIA SYNDROME AFTER HEMATOPOIETIC CELL TRANSPLANT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The idiopathic pneumonia syndrome (IPS) occurs in patients who have undergone either allogeneic or autologous hematopoietic cell transplantation (HCT) and represents a heterogeneous group of noninfectious disorders associated with lung injury that have common pathologic findings of interstitial pneumonitis and/or diffuse alveolar damage.
        </p>
        <p class="headingAnchor" id="H4203798190">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         IPS is characterized by widespread alveolar injury, defined as multilobar opacities on chest radiograph or computed tomography (CT) PLUS signs and symptoms of pneumonia PLUS evidence of abnormal pulmonary physiology manifested by an increased alveolar-arterial oxygen gradient or the need for supplemental oxygen [
         <a href="#rid7">
          7
         </a>
         ]. The clinical presentation is typically an acute onset of dyspnea and cough, with or without fever, and rapid progression to hypoxemia and respiratory failure [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3587943527">
         <span class="h2">
          Timing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The onset of IPS is typically in the first four months following HCT with the majority of cases developing in the pre-engraftment or early post-engraftment phase with median times of onset of 12 to 19 days (range 0 to 112 days) [
         <a href="#rid8">
          8-11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3505075088">
         <span class="h2">
          Incidence and risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         IPS develops in 2 to 10 percent of patients undergoing allogeneic HCT and a smaller portion of those undergoing autologous HCT [
         <a href="#rid7">
          7-9,12,13
         </a>
         ]. Risk factors for IPS include age less than 54 years, prior HCT, prior chest irradiation, total body irradiation as part of the conditioning regimen, presence of acute graft-versus-host disease, and the specific preparative conditioning regimen, including the dose of
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         [
         <a href="#rid8">
          8,9,14-16
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 210 children who underwent allogeneic HCT, 14 (7 percent) developed IPS and risk factors included prior HCT and acute graft-versus-host-disease [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The rate of IPS following allogeneic HCT appears lower in patients who receive reduced intensity conditioning (RIC) regimens compared with a conventional myeloablative conditioning regimen (2.2 versus 8.4 percent) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 4917 patients undergoing autologous HCT for lymphoma, the incidence of IPS was 3 to 6 percent [
         <a href="#rid14">
          14
         </a>
         ]. The incidence was higher among those who received
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         (approximately 450 mg/m
         <sup>
          2
         </sup>
         ), and
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         (CVB; high-dose carmustine, hazard ratio 1.9) with total body irradiation (TBI; HR 2.0), compared with carmustine (low-dose, approximately 300 mg/m
         <sup>
          2
         </sup>
         ), etoposide,
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         (BEAM).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A separate report of 94 patients with Hodgkin lymphoma who received high dose chemotherapy including
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         with autologous HCT found that the incidence of IPS increased with increasing doses of carmustine [
         <a href="#rid15">
          15
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         15 percent incidence with doses less than 475 mg/m
         <sup>
          2
         </sup>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         32 percent with doses between 475 and 525 mg/m
         <sup>
          2
         </sup>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         47 percent with doses greater than 525 mg/m
         <sup>
          2
         </sup>
         (26 percent fatal)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1166367279">
         <span class="h2">
          Evaluation, diagnosis, and treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation, diagnosis, and treatment of IPS following allogeneic and autologous HCT are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">
          "Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Idiopathic pneumonia syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4342.html" rel="external">
          "Pulmonary complications after autologous hematopoietic cell transplantation", section on 'Idiopathic pneumonia syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ACUTE AND SUBACUTE INTERSTITIAL PNEUMONITIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nitrosourea-induced interstitial pneumonitis in the absence of hematopoietic cell transplantation (HCT) is reported in approximately 10 to 30 percent of patients treated with
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         (BCNU) for malignant glioma [
         <a href="#rid17">
          17,18
         </a>
         ] and is also reported after repeated cycles of treatment with
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         (CCNU) and fotemustine [
         <a href="#rid5">
          5,19,20
         </a>
         ]. The onset is generally later than that described after HCT, but typically within 36 months of initiating treatment, and tends to be less fulminant than the IPS reported after HCT.
        </p>
        <p class="headingAnchor" id="H519741011">
         <span class="h2">
          Incidence and risk factors in patients not undergoing HCT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The reported incidence of carmustine-induced pulmonary toxicity has ranged from 20 to 30 percent in some studies, to as low as 1 percent in others [
         <a href="#rid1">
          1
         </a>
         ]. The low incidence of interstitial pneumonitis in some series may be due to a short observation period, low dose
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         therapy, or the short median survival of patients who have received carmustine in the setting of a biologically aggressive, advanced malignancy [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         Several factors have been identified as risk factors for lung toxicity following treatment with
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         (BCNU) or
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         (CCNU), including dose (at least for carmustine; risk is especially high for cumulative doses &gt;1500mg/m
         <sup>
          2
         </sup>
         [
         <a href="#rid21">
          21,22
         </a>
         ])concomitant radiation therapy, concomitant administration of
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , and pre-existing lung disease [
         <a href="#rid3">
          3,18
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the non-HCT setting, dose dependency of lung toxicity has been noted with
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         (BCNU) [
         <a href="#rid18">
          18,21,22
         </a>
         ]. In a study of 73 children with glioma, seven developed interstitial pneumonitis 3 to 11 months after adjuvant chemotherapy with carmustine,
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         [
         <a href="#rid23">
          23
         </a>
         ]. The median cumulative dose of carmustine was 460 mg/m
         <sup>
          2
         </sup>
         . Six of the seven patients died of progressive lung disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is not known if exposure to a single dose of
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         carries a greater or lesser risk of lung toxicity than exposure to the same total dose given in smaller aliquots over a period of one to two years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The risk of pneumonitis in patients treated with
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         for brain cancer or fotemustine appears to be lower than with
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         , but it is not clear that lower doses of either drug are associated with a lower risk:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In two studies of anaplastic oligodendroglioma, a total of 280 patients received
         <a class="drug drug_general" data-topicid="9815" href="/z/d/drug information/9815.html" rel="external">
          procarbazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         (110 to 130 mg/m
         <sup>
          2
         </sup>
         on day 1 every six weeks for four cycles), and
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         (PCV); one patient developed grade 2 to 3 pneumonitis, but none developed pulmonary fibrosis; the median survival was over four years [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A single case report describes one patient who developed progressive and fatal respiratory failure three months after receiving
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         (three doses of 200 mg each at six week intervals) [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In two treatment regimens for malignant glioma that included
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         (90 to 130 mg/m
         <sup>
          2
         </sup>
         per cycle every six weeks), no lung toxicity was reported in the combined total of 204 patients followed up for 9 to 16 months [
         <a href="#rid25">
          25,26
         </a>
         ], although conclusions about safety are limited by the relatively short duration of followup.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Only a few case reports are available regarding pulmonary toxicity with fotemustine. A single case report describes acute interstitial lung disease that developed 20 days after the fourth course of fotemustine monotherapy for metastatic melanoma [
         <a href="#rid5">
          5
         </a>
         ]. The condition regressed spontaneously following drug discontinuation. Another report describes rapidly fatal pulmonary toxicity in of one of 24 patients receiving
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         plus fotemustine for advanced melanoma [
         <a href="#rid27">
          27
         </a>
         ]; however, the attribution of the pulmonary toxicity (dacarbazine versus fotemustine) was not established.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical presentation is heterogeneous. Most patients with nitrosourea-induced interstitial pneumonitis present within weeks to months of treatment with dry cough, breathlessness, and bilateral inspiratory crackles [
         <a href="#rid18">
          18
         </a>
         ]. Others may present within days to weeks of
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         treatment with a fulminant illness similar to acute respiratory distress syndrome (ARDS); however, the patient in this case report had received a high dose of carmustine (1255 mg/m
         <sup>
          2
         </sup>
         ) [
         <a href="#rid28">
          28
         </a>
         ]. Still others may have subclinical disease detected by pulmonary function testing [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1357467807">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation of possible nitrosourea lung toxicity combines assessment of the severity of respiratory impairment with testing to exclude or include other processes. Broad spectrum microbiologic testing, radiographic evaluation, a trial of drug cessation, and bronchoalveolar lavage are the primary ways to narrow the differential diagnosis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory tests
         </strong>
         – The main role of laboratory testing is to determine whether other disease processes are contributing to the patient's respiratory compromise. Thus, complete blood cell counts, coagulation tests, B-type natriuretic peptide (BNP), blood cultures, sputum cultures, and viral serology can be helpful.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Arterial blood gas analysis reveals hypoxemia in advanced cases (with normal or low PaCO
         <sub>
          2
         </sub>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging studies
         </strong>
         – The chest radiograph and computed tomographic (CT) scan appearances are variable. Radiographic imaging most commonly demonstrates bibasilar reticular and micronodular opacities. In fulminant cases, the radiographic picture may suggest pulmonary edema or acute respiratory distress syndrome (ARDS) [
         <a href="#rid18">
          18,28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary function tests
         </strong>
         – The main role for pulmonary function testing is to assess the degree of respiratory impairment by measuring spirometry, diffusing capacity for carbon monoxide, and ambulatory oximetry.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Interstitial pneumonitis may be associated with reduced forced vital capacity (FVC) and total lung capacity (TLC). In addition, a reduced diffusing capacity for carbon monoxide (DLCO) is one of the most sensitive markers of early
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         lung toxicity, and may occur when patients are asymptomatic [
         <a href="#rid2">
          2,17,23
         </a>
         ]. Measurements of DLCO can be a very useful early marker of pulmonary toxicity, since diffusion abnormalities frequently precede the radiologic changes in affected patients [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6972.html" rel="external">
          "Diffusing capacity for carbon monoxide"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bronchoscopy and lung biopsy
         </strong>
         – The main role of bronchoscopy and bronchoalveolar lavage (BAL) is to exclude other processes such as infection, diffuse alveolar hemorrhage, and lymphangitic spread of tumor. Lung biopsy is generally not necessary in suspected nitrosourea lung toxicity, unless symptoms and signs are rapidly progressive and refractory to drug cessation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Histopathology
         </strong>
         – Biopsy and autopsy reports have primarily described interstitial fibrosis with varying degrees of Type II cell hyperplasia, edema, and hyaline membrane formation [
         <a href="#rid28">
          28,29
         </a>
         ]. Electron microscopic studies (performed as part of research) have revealed disappearance of type I pneumocytes, marked hyperplasia and hypertrophy of type II pneumocytes, and interstitial deposits of collagen. Increased expression of fibrogenic factors, including platelet-derived growth factor-B and transforming growth factor beta-1, has also been reported [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H112680347">
         <span class="h2">
          Diagnosis and differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of nitrosourea-induced interstitial pneumonitis is usually based on a history of drug exposure, a compatible clinical picture (cough, dyspnea, decrease in DLCO), and exclusion of alternative diagnoses. The differential diagnosis includes infection, radiation-induced lung injury, pulmonary edema, lung involvement by an underlying malignancy, and pulmonary thromboembolism. (See
         <a class="medical medical_review" href="/z/d/html/4315.html" rel="external">
          "Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal treatment for suspected nitrosourea-induced lung toxicity is not known, although a key initial step is drug cessation for patients receiving ongoing cycles of nitrosourea-containing chemotherapy [
         <a href="#rid5">
          5,17,18
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stopping therapy early based on pulmonary function tests
         </strong>
         – We monitor pulmonary function prior to and during treatment with either
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         or
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         , consistent with United States Food and Drug Administration (FDA)-approved prescribing information [
         <a href="#rid31">
          31,32
         </a>
         ]. Specifically, we measure FVC and DLCO prior to each dose and withdraw the drug if there is a measurable fall (ie, &gt;10 percent) in either [
         <a href="#rid2">
          2,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence in favor of a benefit to stopping
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         at the first sign of lung toxicity comes from a case series in which the reported mortality associated with carmustine-induced interstitial pneumonitis was lower when the drug was stopped at the onset of respiratory symptoms or reduced pulmonary function [
         <a href="#rid2">
          2,17
         </a>
         ]. However, mortality varies substantially among studies, ranging from 16 to 70 percent [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive care
         </strong>
         – In addition to stopping the nitrosourea, supportive care includes supplemental oxygen as needed. (See
         <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">
          "Long-term supplemental oxygen therapy", section on 'Indications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoid treatment
         </strong>
         - Based on clinical experience, for patients with moderate to severe, early-onset nitrosourea-induced pulmonary toxicity (eg, dyspnea at rest, a decrease in oxygen saturation below 90 percent or more than 4 percent decrease from baseline, or worsening clinical status) and no evidence of infection, we suggest initiation of oral glucocorticoid therapy. We typically use a dose equivalent to
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         40 to 60 mg per day, or 1 mg/kg per day, until symptoms and pulmonary function abnormalities improve or resolve [
         <a href="#rid6">
          6,33-36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Studies of glucocorticoid treatment have yielded mixed results, but occasional patients respond. In one series of 73 children receiving a carmustine-based chemotherapy regimen for glioma, seven developed interstitial pneumonitis; only one was successfully treated with glucocorticoids, whereas the others all died [
         <a href="#rid23">
          23
         </a>
         ]. On the other hand, no benefit for glucocorticoids was suggested by case reports of patients who received
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         for brain cancer and developed a rapid onset of respiratory symptoms and fatal respiratory failure despite
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         6 mg daily [
         <a href="#rid19">
          19
         </a>
         ] or
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         10 mg/kg every six hours [
         <a href="#rid37">
          37
         </a>
         ]. High-dose glucocorticoids are often used in patients who develop pneumonitis following
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         in preparation for HCT, although evidence in favor of benefit is minimal. (See
         <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">
          "Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Idiopathic pneumonia syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          LATE ONSET PLEUROPARENCHYMAL FIBROELASTOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients develop a late onset of apical lung disease 2 to 17 years after treatment that is consistent with a rare sub-type of fibrotic interstitial lung disease known as pleuroparenchymal fibroelastosis (PPFE)  (
         <a class="graphic graphic_picture graphicRef71882" href="/z/d/graphic/71882.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid4">
          4,38-43
         </a>
         ]. PPFE can be idiopathic, or may be associated with a chemotherapeutic agent (including nitrosoureas and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ) [
         <a href="#rid40">
          40,41
         </a>
         ], rheumatic disease (eg, Sjögren's disease, systemic sclerosis) [
         <a href="#rid44">
          44
         </a>
         ], aluminosilicate exposure [
         <a href="#rid45">
          45
         </a>
         ], or an idiopathic interstitial pneumonia [
         <a href="#rid46">
          46,47
         </a>
         ]. It has also been described as a late complication of hematopoietic cell and lung transplantation [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         The causality of nitrosoureas in this clinical picture of PPFE has been questioned, largely because of the idiopathic occurrence of the syndrome, lack of a clear dose response relationship, and progression to fibrosis only after a long treatment-free interval [
         <a href="#rid41">
          41
         </a>
         ]. However, factors in favor of an association include the normalcy of pretherapy chest imaging [
         <a href="#rid40">
          40
         </a>
         ], consistent reports of the same distinctive nitrosourea-associated disease from several countries [
         <a href="#rid48">
          48
         </a>
         ], the notion that two separate alkylating agents have been associated with this condition [
         <a href="#rid40">
          40,41
         </a>
         ], and the occurrence of PPFE in young individuals [
         <a href="#rid4">
          4,42
         </a>
         ], in whom fibrotic conditions are relatively rare. The strongest evidence in favor of this association is that histological changes consistent with PPFE were found in all seven subjects who consented to lung biopsy 12 to 17 years after
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         therapy [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16921.html" rel="external">
          "Interpretation of lung biopsy results in interstitial lung disease", section on 'Rare histopathologic interstitial pneumonia patterns'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H41095378">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanism of PPFE due to nitrosoureas is not known and the severity is not always related to the dose of
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         or
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         [
         <a href="#rid4">
          4,38-40,42,43
         </a>
         ]. However, in one series, all of the patients who developed lung toxicity consistent with PPFE had received at least 700 mg/ m
         <sup>
          2
         </sup>
         of carmustine, and 12 of 17 had received &gt;1000 mg/ m
         <sup>
          2
         </sup>
         , including 7 of 9 who died of pulmonary fibrosis [
         <a href="#rid4">
          4,38,42,43
         </a>
         ]. Young age at treatment might also be a risk factor [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="local">
          'Clinical features'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         PPFE after
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         or
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         generally presents with cough, dyspnea, and sometimes chest pain, which may be pleuritic [
         <a href="#rid4">
          4,40-43
         </a>
         ]. The onset of symptoms can be many years after completion of therapy. However, many subjects remain free of symptoms despite restrictive lung function and evidence of PPFE on CT scans and lung biopsies emphasizing the need for careful review of such patients even in the absence of symptoms [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         The following clinical characteristics of late onset fibrosis are drawn from observation of a cohort of 17 pediatric survivors who had been treated with
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         for brain tumors, six of whom died of lung fibrosis (four after a symptom-free interval of 7 to 12 years) [
         <a href="#rid4">
          4
         </a>
         ]. Among the four cases with late onset fibrosis, the mean interval from treatment to first symptoms was nine years, but the interval from first symptoms to death was only one year; all died within two years of their first respiratory symptoms. All had been given 30 to 40 mg
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         daily with no documented benefit.
        </p>
        <p>
         Of the 11 long-term survivors, eight had detailed respiratory follow-up 13 to 17 years post treatment [
         <a href="#rid4">
          4
         </a>
         ]. Most patients had no symptoms for several years, although the chest radiographs and lung function studies showed evidence of lung fibrosis in six of eight cases. All patients had restricted lung function but only one had crackles on chest auscultation. Four patients developed breathlessness or cough. Of the six who had prior spirometry, three had reductions in vital capacity from their initial measurement, but one symptomatic patient had unchanged spirometry over a five-year period.
        </p>
        <p>
         In a later report of this cohort with three additional years of follow-up, two more patients died of pulmonary fibrosis [
         <a href="#rid42">
          42
         </a>
         ]. Notably, there was a significant interaction between age at
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         exposure and the risk of pulmonary fibrosis. In the entire cohort, of the eight patients who died of pulmonary fibrosis, the median age at treatment was 2.5; in contrast the nine-long-term survivors had a median age of treatment of 10 years.
        </p>
        <p class="headingAnchor" id="H2744511161">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most important component of the evaluation of possible PPFE after nitrosourea therapy is high resolution computed tomography (HRCT).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging studies
         </strong>
         – The typical HRCT findings of PPFE include a dense, irregular apical pleural rim, wedge-shaped areas of consolidation that extend into the parenchyma along the septa, and sometimes cephalad retraction of the hila and adjacent traction bronchiectasis [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Changes consistent with PPFE were described in patients who were long-term survivors after childhood treatment with
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         (BCNU) for gliomas: apical pleural thickening, spontaneous pneumothoraces (both usually many months after treatment), and fibrotic "stranding" have been described  (
         <a class="graphic graphic_diagnosticimage graphicRef51903" href="/z/d/graphic/51903.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid4">
          4,38,49
         </a>
         ]. HRCT scans in six patients showed coarse linear strands lying mainly in the upper lobes with some confluent sub-pleural bands that suggested pleural thickening  (
         <a class="graphic graphic_diagnosticimage graphicRef61118" href="/z/d/graphic/61118.html" rel="external">
          image 2
         </a>
         ) [
         <a href="#rid4">
          4,38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Gallium lung scans, which are not typically performed in this setting, were negative in all cases, consistent with noninflammatory fibrosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary function tests
         </strong>
         – Patients with late-presenting
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         lung fibrosis have typically have restricted lung volumes (forced vital capacity [FVC] and total lung capacity [TLC] 50 to 60 percent of predicted values). However, unlike early onset carmustine fibrosis, the DLCO may be normal [
         <a href="#rid4">
          4,40
         </a>
         ]. (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bronchoalveolar lavage (BAL)
         </strong>
         - BAL is generally not needed in the evaluation of PPFE, unless infection is suspected. In the few patients who have undergone BAL, no overall excess of polymorphonuclear cells or lymphocytes (or lymphocyte subsets) was observed on in the lavage fluid [
         <a href="#rid4">
          4
         </a>
         ]. However, mononuclear cells yielded a lower than normal population of mature macrophages and a higher than normal population of immature monocytes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lung pathology
         </strong>
         – Lung biopsy is generally not needed in patients with a clear history of nitrosourea exposure, typical imaging findings, and gradually progressive disease. When obtained, light microscopy reveals interstitial pulmonary fibrosis and elastosis but no inflammatory infiltrate [
         <a href="#rid4">
          4,39,41
         </a>
         ]. The boundary between the pleuropulmonary fibrotic area and normal lung is usually sharp [
         <a href="#rid41">
          41
         </a>
         ]. At autopsy, the lungs show subpleural apical fibrosis  (
         <a class="graphic graphic_picture graphicRef71882" href="/z/d/graphic/71882.html" rel="external">
          picture 1
         </a>
         ). In one series, the type I (membranous) pneumocytes had been shed in some areas, leaving a bare basement membrane [
         <a href="#rid4">
          4
         </a>
         ]. Type II cells had an increased number of lamellar bodies, and some contained multiple large vacuoles.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H41095497">
         <span class="h2">
          Diagnosis and differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of PPFE due to nitrosourea therapy is typically based on the history of exposure and the radiographic appearance on high-resolution CT [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="local">
          'Evaluation'
         </a>
         above.).
        </p>
        <p>
         The differential diagnosis focuses on disease processes that affect the upper lung zones in a subpleural pattern and on other causes of PPFE.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It is important to exclude infection such as tuberculosis and aspergillosis, which have a predilection for the upper lung zones [
         <a href="#rid41">
          41,50
         </a>
         ]. Ankylosing spondylitis can also cause apical fibrosis [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PPFE can be idiopathic [
         <a href="#rid51">
          51
         </a>
         ] or associated with the rheumatic diseases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PPFE can be caused by other chemotherapeutic agents (eg,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [
         <a href="#rid52">
          52,53
         </a>
         ]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pneumonitis due to radiation therapy can cause a similar pattern, if the ports are compatible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asbestosis can cause pleural plaques and interstitial fibrosis, but the changes are more commonly found in the lower lung zones than in the apex [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4307.html" rel="external">
          "Asbestos-related pleuropulmonary disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ergot alkaloid-related pleuropulmonary fibrosis also typically involves the lower lung zones.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Treatment and prognosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         No treatment has been shown to influence the course of PPFE due to nitrosoureas, and supportive care is the primary treatment. The absence of inflammation on CT scans and biopsies suggests that glucocorticoids and immunosuppressive therapy do not have a role in this PPFE. Lung transplantation offers the best hope of long-term survival for severely affected patients.
        </p>
        <p>
         The rate of progression is variable with some patients progressing rapidly to respiratory failure [
         <a href="#rid4">
          4
         </a>
         ] and others remaining stable for many years. The prognosis seems to be much worse for those exposed to nitrosoureas before the age of seven years. In one series, patients who were treated beyond the age of puberty had the best lung function and the slowest rate of decline [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         In a series of nine long-term brain cancer survivors who had serial pulmonary function testing for up to 25 years, a gradual fall in vital capacity and total lung capacity was noted in 6, while 3 patients had stable lung function  (
         <a class="graphic graphic_figure graphicRef51387" href="/z/d/graphic/51387.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid43">
          43
         </a>
         ]. Nine patients eventually died of lung fibrosis, seven of late onset disease. The gradual decline in lung function over many years suggests that patients who have received
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         are potentially at risk of late-presenting lung fibrosis, although as noted above, it appears to be most common when drug exposure occurs before the age of seven. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1390789">
         <span class="h1">
          RECALL PNEUMONITIS AFTER RADIOTHERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radiation recall pneumonitis refers to the development of interstitial pneumonitis following administration of certain antineoplastic agents to patients who have received prior radiation therapy to the lung. In a case report, a patient with lymphoma, who had received irradiation to the chest wall and right lung four and six months previously, developed pneumonitis about seven days after administration of
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         [
         <a href="#rid54">
          54
         </a>
         ]. Based on the chest radiograph, the area of lung injury was limited to the prior radiation therapy ports. (See
         <a class="medical medical_review" href="/z/d/html/4331.html" rel="external">
          "Radiation-induced lung injury", section on 'Prior radiation (recall)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1077544">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The only way to completely avoid the risk of nitrosourea-induced pulmonary toxicity is to avoid the use of nitrosoureas. However, certain general measures may reduce the incidence and severity of lung toxicity:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The lowest possible dose should be used because there is good evidence that higher doses are more likely to cause pulmonary toxicity [
         <a href="#rid15">
          15,21,55
         </a>
         ]. As an example, most hematopoietic cell transplant centers avoid single doses of
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         ≥475 mg/m
         <sup>
          2
         </sup>
         in the conditioning regimen [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="local">
          'Incidence and risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients receiving repeated cycles of nitrosourea chemotherapy, monitoring with serial measures of diffusing capacity for carbon monoxide (DLCO) can help identify early disease. If the DLCO decreases by ≥10 percent, the nitrosourea should be withheld. Additional therapy with glucocorticoids may be indicated. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13506536">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Spectrum of
         </strong>
         <strong>
          adverse pulmonary effects from nitrosourea drugs
         </strong>
         – The nitrosourea drugs are DNA alkylating agents that are associated with idiopathic pneumonia syndrome, interstitial pneumonitis (usually within three years of treatment) and late-onset fibrosis (pleuroparenchymal fibroelastosis [PPFE], often occurring many years after treatment).
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          Carmustine
         </a>
         (BCNU) is the most commonly used nitrosourea. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Idiopathic pneumonia syndrome
         </strong>
         – The idiopathic pneumonia syndrome (IPS) develops in approximately 10 percent of patients up to four months after undergoing hematopoietic cell transplantation (HCT). While the etiology of IPS is likely multifactorial,
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         and
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         have been used in the preparative regimen for HCT in patients with Hodgkin lymphoma and other malignancies and may be contributing factors. (See
         <a class="local">
          'Idiopathic pneumonia syndrome after hematopoietic cell transplant'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">
          "Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Idiopathic pneumonia syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interstitial pneumonitis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Risk factors
         </strong>
         – Risk factors for interstitial pneumonitis include higher doses (especially doses above 1500 m
         <sup>
          g
         </sup>
         /m
         <sup>
          2
         </sup>
         ), the concurrent administration of other agents that cause pulmonary toxicity (eg,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ), and possibly underlying lung disease, localized chest wall radiotherapy, and atopy. (See
         <a class="local">
          'Acute and subacute interstitial pneumonitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The diagnosis of early-onset nitrosourea-indued lung toxicity is usually established based upon a history of drug exposure and a compatible clinical picture, but it is a diagnosis of exclusion. The differential diagnosis includes radiation-induced lung injury, pulmonary edema, lung involvement by an underlying malignancy, and pulmonary thromboembolism. (See
         <a class="local">
          'Diagnosis and differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Monitoring and threshold for discontinuation
         </strong>
         – For patients receiving ongoing treatment (eg, repeated cycles for a solid tumor) with
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         or
         <a class="drug drug_general" data-topicid="9569" href="/z/d/drug information/9569.html" rel="external">
          lomustine
         </a>
         , most experts, including the authors and editors of this topic review, measure forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) prior to each dose and withdraw the drug if there is a measurable fall (ie, &gt;10 percent) in either. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Systemic glucocorticoid therapy
         </strong>
         – For those patients with moderate to severe, early-onset nitrosourea-induced pulmonary toxicity (eg, dyspnea at rest, a decrease in oxygen saturation below 90 percent or more than 4 percent decrease from baseline, or worsening clinical status) and no evidence of infection, we suggest administering systemic glucocorticoid therapy, rather than observation and supportive care alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The initial dose is the equivalent of oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         40 to 60 mg/day or 1 mg/kg daily. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Late onset pleuroparenchymal fibroelastosis
         </strong>
         – High doses of
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         are also a risk factor for late-onset PPFE, which is fatal in approximately 50 percent and associated with radiographic or physiologic evidence of pulmonary fibrosis in long-term survivors. (See
         <a class="local">
          'Late onset pleuroparenchymal fibroelastosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical and radiographic features
         </strong>
         – Late onset PPFE typically presents with gradual onset of dyspnea and cough several years following cessation of
         <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">
          carmustine
         </a>
         . The main radiographic findings are a dense, irregular apical pleural rim, wedge-shaped areas of consolidation that extend into the parenchyma along the septa, and sometimes cephalad retraction of the hila and adjacent traction bronchiectasis. Pulmonary function tests show a restrictive pattern. (See
         <a class="local">
          'Clinical features'
         </a>
         above and
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of PPFE is usually based on the clinical features, history of nitrosourea exposure, and the HRCT pattern. (See
         <a class="local">
          'Diagnosis and differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Treatment
         </strong>
         – No treatment has been shown to influence the course of late nitrosourea-induced PPFE. Based on the histopathologic appearance of fibrosis without inflammation, glucocorticoids do not have a role. Lung transplantation may be an option. (See
         <a class="local">
          'Treatment and prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2380577849">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Ronan O’Driscoll, BSc, MD, FRCP, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Weiss RB, Poster DS, Penta JS. The nitrosoureas and pulmonary toxicity. Cancer Treat Rev 1981; 8:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selker RG, Jacobs SA, Moore PB, et al. 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced pulmonary fibrosis. Neurosurgery 1980; 7:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durant JR, Norgard MJ, Murad TM, et al. Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). Ann Intern Med 1979; 90:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Driscoll BR, Hasleton PS, Taylor PM, et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 1990; 323:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertrand M, Wémeau-Stervinou L, Gauthier S, et al. [New toxicity of fotemustine: diffuse interstitial lung disease]. Ann Dermatol Venereol 2012; 139:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alessandrino EP, Bernasconi P, Colombo A, et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000; 25:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panoskaltsis-Mortari A, Griese M, Madtes DK, et al. An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med 2011; 183:1262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahya VN. Noninfectious Acute Lung Injury Syndromes Early After Hematopoietic Stem Cell Transplantation. Clin Chest Med 2017; 38:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sano H, Kobayashi R, Iguchi A, et al. Risk factor analysis of idiopathic pneumonia syndrome after allogeneic hematopoietic SCT in children. Bone Marrow Transplant 2014; 49:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tizon R, Frey N, Heitjan DF, et al. High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. Bone Marrow Transplant 2012; 47:1332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yanik GA, Horowitz MM, Weisdorf DJ, et al. Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol. Biol Blood Marrow Transplant 2014; 20:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wadhwa PD, Fu P, Koc ON, et al. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality. Biol Blood Marrow Transplant 2005; 11:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Afessa B, Abdulai RM, Kremers WK, et al. Risk factors and outcome of pulmonary complications after autologous hematopoietic stem cell transplant. Chest 2012; 141:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen YB, Lane AA, Logan BR, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015; 21:1046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubio C, Hill ME, Milan S, et al. Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease. Br J Cancer 1997; 75:1044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukuda T, Hackman RC, Guthrie KA, et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003; 102:2777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstein AS, Diener-West M, Nelson DF, Pakuris E. Pulmonary toxicity of carmustine in patients treated for malignant glioma. Cancer Treat Rep 1986; 70:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith AC. The pulmonary toxicity of nitrosoureas. Pharmacol Ther 1989; 41:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dent RG. Fatal pulmonary toxic effects of lomustine. Thorax 1982; 37:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cordonnier C, Vernant JP, Mital P, et al. Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia. Cancer 1983; 51:1814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmitz N, Diehl V. Carmustine and the lungs . Lancet 1997; 349:1712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aronin PA, Mahaley MS Jr, Rudnick SA, et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. N Engl J Med 1980; 303:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chastagner P, Kalifa C, Doz F, et al. Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study. Pediatr Blood Cancer 2007; 49:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27:5874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010; 28:1168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014; 15:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerard B, Aamdal S, Lee SM, et al. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma. Eur J Cancer 1993; 29A:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitsudo SM, Greenwald ES, Banerji B, Koss LG. BCNU (1,3-bis-(2-chloroethyl)-1-nitrosurea) lung. Drug-induced pulmonary changes. Cancer 1984; 54:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan BR, Walters TR. Pulmonary fibrosis: a complication of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy. Cancer 1981; 48:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen YC, Chiu CF, Chow KC, et al. Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2. Bone Marrow Transplant 2004; 34:609.
          </a>
         </li>
         <li class="breakAll">
          Label information for BICNU carmustine injection kit. DailyMed, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6cbb63c-e0b1-43ee-ad6f-408da0772079 (Accessed on October 11, 2023).
         </li>
         <li class="breakAll">
          Label information for GLEOSTINE lomustine capsules. DailyMed, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f77526b-4c40-409c-82ea-d0f934d89cc2 (Accessed on October 11, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cao TM, Negrin RS, Stockerl-Goldstein KE, et al. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000; 6:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chap L, Shpiner R, Levine M, et al. Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment. Bone Marrow Transplant 1997; 20:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalaycioglu M, Kavuru M, Tuason L, Bolwell B. Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU). Chest 1995; 107:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sivaraj D, Bacon W, Long GD, et al. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplant 2018; 53:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radhakrishnan V, Perumal J, Sundersingh S, Sagar T. Lomustine induced acute pulmonary toxicity in a pediatric medulloblastoma survivor. South Asian J Cancer 2017; 6:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor PM, O'Driscoll BR, Gattamaneni HR, Woodcock AA. Chronic lung fibrosis following carmustine (BCNU) chemotherapy: radiological features. Clin Radiol 1991; 44:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasleton PS, O'Driscoll BR, Lynch P, et al. Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma. J Pathol 1991; 164:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beynat-Mouterde C, Beltramo G, Lezmi G, et al. Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents. Eur Respir J 2014; 44:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camus P, von der Thüsen J, Hansell DM, Colby TV. Pleuroparenchymal fibroelastosis: one more walk on the wild side of drugs? Eur Respir J 2014; 44:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Driscoll BR, Kalra S, Gattamaneni HR, Woodcock AA. Late carmustine lung fibrosis. Age at treatment may influence severity and survival. Chest 1995; 107:1355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lohani S, O'Driscoll BR, Woodcock AA. 25-year study of lung fibrosis following carmustine therapy for brain tumor in childhood. Chest 2004; 126:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enomoto Y, Nakamura Y, Colby TV, et al. Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease. PLoS One 2017; 12:e0180283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang Z, Li S, Zhu Y, et al. Pleuroparenchymal fibroelastosis associated with aluminosilicate dust: a case report. Int J Clin Exp Pathol 2015; 8:8676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oda T, Ogura T, Kitamura H, et al. Distinct characteristics of pleuroparenchymal fibroelastosis with usual interstitial pneumonia compared with idiopathic pulmonary fibrosis. Chest 2014; 146:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakatani T, Arai T, Kitaichi M, et al. Pleuroparenchymal fibroelastosis from a consecutive database: a rare disease entity? Eur Respir J 2015; 45:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von der Thüsen JH. Pleuroparenchymal Fibroelastosis: Its Pathological Characteristics. Curr Respir Med Rev 2013; 9:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parish JM, Muhm JR, Leslie KO. Upper lobe pulmonary fibrosis associated with high-dose chemotherapy containing BCNU for bone marrow transplantation. Mayo Clin Proc 2003; 78:630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawaguchi T, Oda K, Kido T, et al. Bilateral Tuberculous Pleurisy with Subsequent Upper Lobe Predominant Pulmonary Fibrosis Mimicking Pleuroparenchymal Fibroelastosis. Intern Med 2018; 57:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurtado EJ, González ML, Soto Mdel M, et al. Idiopathic pleuroparenchymal fibroelastosis, a new idiopathic interstitial pneumonia: A case report. Chron Respir Dis 2016; 13:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stentoft J. Progressive pulmonary fibrosis complicating cyclophosphamide therapy. Acta Med Scand 1987; 221:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 1996; 154:1851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas PS, Agrawal S, Gore M, Geddes DM. Recall lung pneumonitis due to carmustine after radiotherapy. Thorax 1995; 50:1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ager S, Mahendra P, Richards EM, et al. High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study. Bone Marrow Transplant 1996; 17:335.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4354 Version 23.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6454489" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The nitrosoureas and pulmonary toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7207751" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/443651" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2370889" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22482481" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : [New toxicity of fotemustine: diffuse interstitial lung disease].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10673703" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21531955" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29128012" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Noninfectious Acute Lung Injury Syndromes Early After Hematopoietic Stem Cell Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23955635" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Risk factor analysis of idiopathic pneumonia syndrome after allogeneic hematopoietic SCT in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22307018" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24607553" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15625540" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21778261" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Risk factors and outcome of pulmonary complications after autologous hematopoietic stem cell transplant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25687795" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9083341" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12855568" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3524837" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pulmonary toxicity of carmustine in patients treated for malignant glioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2654964" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The pulmonary toxicity of nitrosoureas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7179192" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Fatal pulmonary toxic effects of lomustine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6572542" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9193378" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Carmustine and the lungs .
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7383088" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17096408" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19901110" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20124186" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25035291" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8471329" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6744207" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : BCNU (1,3-bis-(2-chloroethyl)-1-nitrosurea) lung. Drug-induced pulmonary changes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7272934" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Pulmonary fibrosis: a complication of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15286697" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15286697" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15286697" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10917574" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9466279" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7842781" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29084203" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28413799" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Lomustine induced acute pulmonary toxicity in a pediatric medulloblastoma survivor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1760904" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Chronic lung fibrosis following carmustine (BCNU) chemotherapy: radiological features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2056387" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24791830" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25082907" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Pleuroparenchymal fibroelastosis: one more walk on the wild side of drugs?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7750330" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Late carmustine lung fibrosis. Age at treatment may influence severity and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15364795" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : 25-year study of lung fibrosis following carmustine therapy for brain tumor in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28666014" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26339456" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Pleuroparenchymal fibroelastosis associated with aluminosilicate dust: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25367470" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Distinct characteristics of pleuroparenchymal fibroelastosis with usual interstitial pneumonia compared with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25700380" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Pleuroparenchymal fibroelastosis from a consecutive database: a rare disease entity?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24634642" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Pleuroparenchymal Fibroelastosis: Its Pathological Characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12744552" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Upper lobe pulmonary fibrosis associated with high-dose chemotherapy containing BCNU for bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29033441" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Bilateral Tuberculous Pleurisy with Subsequent Upper Lobe Predominant Pulmonary Fibrosis Mimicking Pleuroparenchymal Fibroelastosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26810762" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Idiopathic pleuroparenchymal fibroelastosis, a new idiopathic interstitial pneumonia: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3604756" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Progressive pulmonary fibrosis complicating cyclophosphamide therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8970380" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Lung toxicity associated with cyclophosphamide use. Two distinct patterns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7491565" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Recall lung pneumonitis due to carmustine after radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8704683" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
